Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens

Autoimmunity Reviews

Volumn 12, Issue 9, 2013, Pages 924-930

  Zisimopoulou, Paraskevi ^a   Brenner, Talma ^b   Trakas, Nikolaos ^a   Tzartos, Socrates J ^a  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

AChR; Autoantibodies; Cell based assay; Diagnostic assays; LRP4; MuSK; Myasthenia gravis; Radioimmunoprecipitation

Indexed keywords

ACTIN; ACTININ; ANTIGEN; AUTOANTIBODY; AUTOANTIGEN; CONNECTIN; FILAMIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 4; MYOSIN; RYANODINE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; MYASTHENIA GRAVIS; NONHUMAN; PATHOGENICITY; PATHOPHYSIOLOGY; RADIOIMMUNOPRECIPITATION; REVIEW; SARCOPLASMIC RETICULUM; SERODIAGNOSIS; THYMOMA;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; CONNECTIN; HUMANS; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; RADIOIMMUNOPRECIPITATION ASSAY; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; THYMOMA;

EID: 84879129714     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.03.002     Document Type: Review

References (92)

1. Paton W.D., Waud D.R. The margin of safety of neuromuscular transmission. J Physiol 1967, 191:59-90.
2. Sanes J.R., Lichtman J.W. Induction, assembly, maturation and maintenance of a postsynaptic apparatus. Nat Rev Neurosci 2001, 2:791-805.
3. Kummer T.T., Misgeld T., Sanes J.R. Assembly of the postsynaptic membrane at the neuromuscular junction: paradigm lost. Curr Opin Neurobiol 2006, 16:74-82.
4. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001, 7:365-368.
5. Zhang B., Tzartos J.S., Belimezi M., Ragheb S., Bealmear B., Lewis R.A., et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2011, 69:445-451.
6. Higuchi O., Hamuro J., Motomura M., Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011, 69:418-422.
7. Pevzner A., Schoser B., Peters K., Cosma N.C., Karakatsani A., Schalke B., et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2011, 259:427-435.
8. Marx A., Pfister F., Schalke B., Saruhan-Direskeneli G., Melms A., Ströbel P. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 2013, 12(9):875-884. (this issue).
9. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976, 26:1054-1059.
10. Sine S.M. Functional properties of human skeletal muscle acetylcholine receptors expressed by the TE671 cell line. J Biol Chem 1988, 263:18052-18062.
11. Vincent A., Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985, 48:1246-1252.
12. Matthews I., Chen S., Hewer R., McGrath V., Furmaniak J., Rees Smith B. Muscle-specific receptor tyrosine kinase autoantibodies-a new immunoprecipitation assay. Clin Chim Acta 2004, 348:95-99.
13. Buckley C., Vincent A. Autoimmune channelopathies. Nat Clin Pract Neurol 2005, 1:22-33.
14. Vincent A., Bien C.G., Irani S.R., Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011, 10:759-772.
15. MacLennan C., Beeson D., Buijs A.M., Vincent A., Newsom-Davis J. Acetylcholine receptor expression in human extraocular muscles and their susceptibility to myasthenia gravis. Ann Neurol 1997, 41:423-431.
16. Ohta K., Fujinami A., Saida T., Nishimura M., Kuno S., Ohta M. Frequency of anti-AChR epsilon subunit-specific antibodies in MG. Autoimmunity 2003, 36:151-154.
17. Leite M.I., Waters P., Vincent A. Diagnostic use of autoantibodies in myasthenia gravis. Autoimmunity 2010, 43:371-379.
18. Beeson D., Amar M., Bermudez I., Vincent A., Newsom-Davis J. Stable functional expression of the adult subtype of human muscle acetylcholine receptor following transfection of the human rhabdomyosarcoma cell line TE671 with cDNA encoding the epsilon subunit. Neurosci Lett 1996, 207:57-60.
19. Tindall R.S. Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations. Ann Neurol 1981, 10:437-447.
20. Trakas N., Zisimopoulou P., Tzartos S.J. Development of a highly sensitive diagnostic assay for muscle-specific tyrosine kinase (MuSK) autoantibodies in myasthenia gravis. J Neuroimmunol 2011, 240-241:79-86.
21. Leite M.I., Jacob S., Viegas S., Cossins J., Clover L., Morgan B.P., et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008, 131:1940-1952.
22. Jacob S., Viegas S., Leite M.I., Webster R., Cossins J., Kennett R., et al. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol 2012, 69:994-1001.
23. Shi Q.G., Wang Z.H., Ma X.W., Zhang D.Q., Yang C.S., Shi F.D., et al. Clinical significance of detection of antibodies to fetal and adult acetylcholine receptors in myasthenia gravis. Neurosci Bull 2012, 28:469-474.
24. Yang L., Maxwell S., Leite M.I., Waters P., Clover L., Fan X., et al. Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China. J Neurol Sci 2011, 301:71-76.
25. McConville J., Farrugia M.E., Beeson D., Kishore U., Metcalfe R., Newsom-Davis J., et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004, 55:580-584.
26. Furukawa S., Akazawa S., Furukawa Y., Kamo I., Satoyoshi E., Hayashi K. A practical enzyme immunoassay for anti-acetylcholine receptor antibodies in myasthenia gravis. J Neuroimmunol 1984, 6:397-409.
27. Hewer R., Matthews I., Chen S., McGrath V., Evans M., Roberts E., et al. A sensitive non-isotopic assay for acetylcholine receptor autoantibodies. Clin Chim Acta 2006, 364:159-166.
28. Burbelo P.D., Ching K.H., Bush E.R., Han B.L., Iadarola M.J. Antibody-profiling technologies for studying humoral responses to infectious agents. Expert Rev Vaccines 2010, 9:567-578.
29. Ching K.H., Burbelo P.D., Kimball R.M., Clawson L.L., Corse A.M., Iadarola M.J. Recombinant expression of the AChR-alpha1 subunit for the detection of conformation-dependent epitopes in myasthenia gravis. Neuromuscul Disord 2010, 21:204-213.
30. Evoli A., Tonali P.A., Padua L., Monaco M.L., Scuderi F., Batocchi A.P., et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003, 126:2304-2311.
31. Farrugia M.E., Kennett R.P., Newsom-Davis J., Hilton-Jones D., Vincent A. Single-fiber electromyography in limb and facial muscles in muscle-specific kinase antibody and acetylcholine receptor antibody myasthenia gravis. Muscle Nerve 2006, 33:568-570.
32. Niks E.H., Kuks J.B., Roep B.O., Haasnoot G.W., Verduijn W., Ballieux B.E., et al. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology 2006, 66:1772-1774.
33. Evoli A., Padua L. Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmun Rev 2013, 12(9):931-935. (this issue).
34. Verschuuren J.J.G.M., Huijbers M.G., Plomp J.J., Niks E.H., Molenaar P.C., Martinez P.M., et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev 2013, 12(9):918-923. (this issue).
35. Vincent A., Drachman D.B. Myasthenia gravis. Adv Neurol 2002, 88:159-188.
36. Le Panse R., Cizeron-Clairac G., Bismuth J., Berrih-Aknin S. Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia. J Immunol 2006, 177:7868-7879.
37. Leite M.I., Jones M., Strobel P., Marx A., Gold R., Niks E., et al. Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol 2007, 171:893-905.
38. Tzartos S.J., Barkas T., Cung M.T., Mamalaki A., Marraud M., Orlewski P., et al. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev 1998, 163:89-120.
39. Tzartos S., Langeberg L., Hochschwender S., Lindstrom J. Demonstration of a main immunogenic region on acetylcholine receptors from human muscle using monoclonal antibodies to human receptor. FEBS Lett 1983, 158:116-118.
40. Lindstrom J., Luo J., Kuryatov A. Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains. Ann N Y Acad Sci 2008, 1132:29-41.
41. Psaridi-Linardaki L., Mamalaki A., Remoundos M., Tzartos S.J. Expression of soluble ligand- and antibody-binding extracellular domain of human muscle acetylcholine receptor alpha subunit in yeast Pichia pastoris. Role of glycosylation in alpha-bungarotoxin binding. J Biol Chem 2002, 277:26980-26986.
42. Psaridi-Linardaki L., Trakas N., Mamalaki A., Tzartos S.J. Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen-specific therapeutic strategy. J Neuroimmunol 2005, 159:183-191.
43. Kostelidou K., Trakas N., Tzartos S.J. Extracellular domains of the beta, gamma and epsilon subunits of the human acetylcholine receptor as immunoadsorbents for myasthenic autoantibodies: a combination of immunoadsorbents results in increased efficiency. J Neuroimmunol 2007, 190:44-52.
44. Bitzopoulou K., Kostelidou K., Poulas K., Tzartos S.J. Mutant forms of the extracellular domain of the human acetylcholine receptor gamma-subunit with improved solubility and enhanced antigenicity. The importance of the Cys-loop. Biochim Biophys Acta 2008, 1784:1226-1233.
45. Zisimopoulou P., Lagoumintzis G., Poulas K., Tzartos S.J. Antigen-specific apheresis of human anti-acetylcholine receptor autoantibodies from myasthenia gravis patients' sera using Escherichia coli-expressed receptor domains. J Neuroimmunol 2008, 200:133-141.
46. Lindstrom J.M., Engel A.G., Seybold M.E., Lennon V.A., Lambert E.H. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies. J Exp Med 1976, 144:739-753.
47. Lang B., Newsom-Davis J., Prior C., Wray D. Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse. J Physiol 1983, 344:335-345.
48. Mossman S., Vincent A., Newsom-Davis J. Passive transfer of myasthenia gravis by immunoglobulins: lack of correlation between AChR with antibody bound, acetylcholine receptor loss and transmission defect. J Neurol Sci 1988, 84:15-28.
49. Shillito P., Molenaar P.C., Vincent A., Leys K., Zheng W., van den Berg R.J., et al. Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol 1995, 38:714-722.
50. Engel A.G., Lambert E.H., Mulder D.M., Torres C.F., Sahashi K., Bertorini T.E., et al. A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann Neurol 1982, 11:553-569.
51. Pinching A.J., Peters D.K., Newsom-Davis J. Remission of myasthenia gravis following plasma-exchange. Lancet 1976, 2:1373-1376.
52. Dau P.C., Lindstrom J.M., Cassel C.K., Denys E.H., Shev E.E., Spitler L.E. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med 1977, 297:1134-1140.
53. Patrick J., Lindstrom J. Autoimmune response to acetylcholine receptor. Science 1973, 180:871-872.
54. Tzartos S., Hochschwender S., Vasquez P., Lindstrom J. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J Neuroimmunol 1987, 15:185-194.
55. Tzartos S.J., Bitzopoulou K., Gavra I., Kordas G., Jacobson L., Kostelidou K., et al. Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera. Ann N Y Acad Sci 2008, 1132:291-299.
56. Sanders D.B., El-Salem K., Massey J.M., McConville J., Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003, 60:1978-1980.
57. Romi F., Aarli J.A., Gilhus N.E. Seronegative myasthenia gravis: disease severity and prognosis. Eur J Neurol 2005, 12:413-418.
58. Guptill J.T., Sanders D.B. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol 2010, 23:530-535.
59. Bartoccioni E., Scuderi F., Minicuci G.M., Marino M., Ciaraffa F., Evoli A. Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 2006, 67:505-507.
60. Vincent A. Immunology of disorders of neuromuscular transmission. Acta Neurol Scand Suppl 2006, 183:1-7.
61. Niks E.H., van Leeuwen Y., Leite M.I., Dekker F.W., Wintzen A.R., Wirtz P.W., et al. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J Neuroimmunol 2008, 195:151-156.
62. Selcen D., Fukuda T., Shen X.M., Engel A.G. Are MuSK antibodies the primary cause of myasthenic symptoms?. Neurology 2004, 62:1945-1950.
63. Shiraishi H., Motomura M., Yoshimura T., Fukudome T., Fukuda T., Nakao Y., et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005, 57:289-293.
64. Verschuuren J.J., Palace J., Gilhus N.E. Clinical aspects of myasthenia explained. Autoimmunity 2010, 43:344-352.
65. Boneva N., Frenkian-Cuvelier M., Bidault J., Brenner T., Berrih-Aknin S. Major pathogenic effects of anti-MuSK antibodies in myasthenia gravis. J Neuroimmunol 2006, 177:119-131.
66. Cole R.N., Reddel S.W., Gervasio O.L., Phillips W.D. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 2008, 63:782-789.
67. Cole R.N., Ghazanfari N., Ngo S.T., Gervasio O.L., Reddel S.W., Phillips W.D. Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice. J Physiol 2010, 588:3217-3229.
68. Klooster R., Plomp J.J., Huijbers M.G., Niks E.H., Straasheijm K.R., Detmers F.J., et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 2012, 135:1081-1101.
69. Shultz L.D., Schweitzer P.A., Christianson S.W., Gott B., Schweitzer I.B., Tennent B., et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995, 154:180-191.
70. Vincent A., Leite M.I., Farrugia M.E., Jacob S., Viegas S., Shiraishi H., et al. Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann N Y Acad Sci 2008, 1132:84-92.
71. Vincent A., Newsom-Davis J. Acetylcholine receptor antibody characteristics in myasthenia gravis. II. Patients with penicillamine-induced myasthenia or idiopathic myasthenia of recent onset. Clin Exp Immunol 1982, 49:266-272.
72. Engel A.G., Lambert E.H., Howard F.M. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 1977, 52:267-280.
73. Tsujihata M., Yoshimura T., Satoh A., Kinoshita I., Matsuo H., Mori M., et al. Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end-plate in minimal myasthenia gravis. Neurology 1989, 39:1359-1363.
74. Williams C.L., Lennon V.A. Thymic B lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational autoantibodies reacting with myosin, alpha actinin, or actin. J Exp Med 1986, 164:1043-1059.
75. Yamamoto T., Sato T., Sugita H. Antifilamin, antivinculin, and antitropomyosin antibodies in myasthenia gravis. Neurology 1987, 37:1329-1333.
76. Ohta M., Ohta K., Itoh N., Kurobe M., Hayashi K., Nishitani H. Anti-skeletal muscle antibodies in the sera from myasthenic patients with thymoma: identification of anti-myosin, actomyosin, actin, and alpha-actinin antibodies by a solid-phase radioimmunoassay and a western blotting analysis. Clin Chim Acta 1990, 187:255-264.
77. Aarli J.A., Lefvert A.K., Tonder O. Thymoma-specific antibodies in sera from patients with myasthenia gravis demonstrated by indirect haemagglutination. J Neuroimmunol 1981, 1:421-427.
78. Aarli J.A. Late-onset myasthenia gravis: a changing scene. Arch Neurol 1999, 56:25-27.
79. Granzier H., Labeit S. Structure-function relations of the giant elastic protein titin in striated and smooth muscle cells. Muscle Nerve 2007, 36:740-755.
80. Gautel M., Lakey A., Barlow D.P., Holmes Z., Scales S., Leonard K., et al. Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin. Neurology 1993, 43:1581-1585.
81. Mygland A., Tysnes O.B., Matre R., Volpe P., Aarli J.A., Gilhus N.E. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Ann Neurol 1992, 32:589-591.
82. Mygland A., Tysnes O.B., Matre R., Aarli J.A., Gilhus N.E. Anti-cardiac ryanodine receptor antibodies in thymoma-associated myasthenia gravis. Autoimmunity 1994, 17:327-331.
83. Romi F., Gilhus N.E., Aarli J.A. Myasthenia gravis: clinical, immunological, and therapeutic advances. Acta Neurol Scand 2005, 111:134-141.
84. Romi F., Skeie G.O., Aarli J.A., Gilhus N.E. Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol 2000, 247:369-375.
85. Buckley C., Newsom-Davis J., Willcox N., Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?. Neurology 2001, 57:1579-1582.
86. Romi F. Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmun Rev 2011, 2011:474512.
87. Zisimopoulou P., Tzartos J., Evangelakou P., Tsonis A., Trakas N., Evoli A., et al. A multinational study on the detection of autoantibodies to the novel antigen LRP4, in double seronegative myasthenia gravis patient sera. 12th International Conference on Myasthenia Gravis and Related Disorders, May 21-23 2012, The New York Academy of Sciences.
88. van der Neut Kolfschoten M., Schuurman J., Losen M., Bleeker W.K., Martinez-Martinez P., Vermeulen E., et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007, 317:1554-1557.
89. Weatherbee S.D., Anderson K.V., Niswander L.A. LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction. Development 2006, 133:4993-5000.
90. Kim N., Stiegler A.L., Cameron T.O., Hallock P.T., Gomez A.M., Huang J.H., et al. Lrp4 is a receptor for agrin and forms a complex with MuSK. Cell 2008, 135:334-342.
91. Zhang B., Luo S., Wang Q., Suzuki T., Xiong W.C., Mei L. LRP4 serves as a coreceptor of agrin. Neuron 2008, 60:285-297.
92. Belaya K., Cossins J., Zoltowska K., Leite I., Koneczny I., Waters P., et al. The search for new antigenic targets in myasthenia gravis. 12th International Conference on Myasthenia Gravis and Related Disorders, May 21-23 2012, The New York Academy of Sciences.